UBS lowered the firm’s price target on GoodRx (GDRX) to $5.25 from $6 and keeps a Neutral rating on the shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- GoodRx Reports Strong Q1 2025 Results
- Positive Outlook on GoodRx Holdings: Strong Growth Potential and Strategic Positioning Justify Buy Rating
- Hold Rating for GoodRx Holdings Amid Revenue Challenges and Uncertainties
- GoodRx Earnings Call: Mixed Sentiment with Growth and Challenges
- GoodRx price target lowered to $4 from $4.75 at BofA